We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
WALTHAM, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group , to evaluate the combination of the PD-L1 antibody
View HTML
Toggle Summary TESARO Summarizes TOPACIO and QUADRA Trial Results Presented at 2018 ASCO Annual Meeting
TOPACIO data for ZEJULA ® (niraparib) in combination with an anti-PD-1 mAb highlight promising activity in platinum-resistant/refractory ovarian cancer and triple-negative breast cancer beyond patients with BRCA mutations and support initiation of registration trials QUADRA results demonstrate
View HTML
Toggle Summary TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK
Inclusion in the Cancer Drugs Fund will give more women in England and Wales with recurrent, platinum-sensitive ovarian cancer access to ZEJULA via a managed access arrangement ZEJULA was launched in the private market in the UK at the end of 2017 ZUG, Switzerland , June 01, 2018 (GLOBE NEWSWIRE)
View HTML
Toggle Summary TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass. , May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five ZEJULA ® (niraparib) abstracts, including two oral
View HTML
Toggle Summary PSYCHOLOGICAL EFFECTS OF OVARIAN CANCER OFTEN OVERLOOKED, BUT CAN HAVE A SIGNIFICANT IMPACT ON PATIENTS – NEW EUROPEAN LITERATURE REVIEW REVEALS
79% of patients felt uncomfortable raising psychological and emotional concerns during their consultations 1 Disease recurrence is of greatest concern for ovarian cancer patients, but poorly addressed, with 53% of patients saying symptoms of recurrence have not been discussed with them 2
View HTML
Toggle Summary TESARO Announces First-Quarter 2018 Operating Results
ZEJULA Q1 net sales totaled $49 million Enrollment completed in Phase 3 PRIMA first-line ovarian cancer monotherapy trial TOPACIO platinum-resistant ovarian cancer and triple-negative breast cancer data accepted for oral presentations at ASCO Initial data from two TSR-042 (anti-PD-1) GARNET
View HTML
Toggle Summary TESARO Announces Participation in Two Investor Conferences
WALTHAM, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Bank of America Merrill Lynch 2018 Healthcare Conference at the Encore
View HTML
Toggle Summary TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®
Results demonstrate ZEJULA activity beyond patients with BRCA mutations in late-line ovarian cancer treatment setting QUADRA data accepted for presentation at 2018 ASCO annual meeting Data intended to support label expansion with biomarker in the treatment setting WALTHAM, Mass.
View HTML
Toggle Summary TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce first-quarter 2018 financial results on Thursday, May 3, 2018 , after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15 p.m.
View HTML
Toggle Summary TESARO to Receive 2018 Partnership Award at CancerCare® Gala
TESARO to Receive 2018 Partnership Award at Cancer Care® Gala - NEW YORK, April 19, 2018 – Cancer Care ®, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, announced that TESARO will receive their 2018 Partnership
View HTML